Why the study?
The study sought to determine the potential of extracellular vesicle microRNAs to serve as early diagnostic biomarkers for acute myocardial infarction.
Do serum extracellular vesicle-derived microRNA profiles differ between patients with acute myocardial infarction and healthy controls?
Do serum extracellular vesicle-derived microRNA profiles differ between patients with acute myocardial infarction and healthy controls?
Serum extracellular vesicle-derived miRNAs show distinct differential expression profiles in AMI patients, suggesting their potential utility as early diagnostic biomarkers.
EV miRNA differences in small AMI cohorts are hypothesis-generating; larger prospective studies needed before diagnostic use.
Objective: In this study, we sought to determine the potential of extracellular vesicle (EV) microRNAs (miRNAs) to serve as early diagnostic biomarkers for AMI. Method: Peripheral blood samples were collected from three patients with AMI and three healthy individuals, and serum EV total RNA was extracted. The miRNA differential expression profiles of serum EVs were obtained through next-generation sequencing combined with bioinformatics analysis. Results: In patients with AMI, compared with controls without AMI, 15 differentially expressed miRNAs (11 upregulated and 4 downregulated) were identified. GO analysis predicted 842 target genes. Enrichment analysis revealed 639 genes involved in biological processes, 592 genes involved in molecular function, and 692 genes involved in cellular components. KEGG analysis indicated that the protein processing in the endoplasmic reticulum pathway, P53 pathway, and mRNA surveillance signaling pathway significantly correlated with AMI. PPI network analysis indicated that 842 target proteins and 10 hub genes were significantly associated with the miRNAs. Conclusion: We identified 15 significantly differentially expressed miRNAs in AMI, whose target genes significantly correlated with protein processing in the endoplasmic reticulum pathway and the P53 pathway. Our results provide a reference for use of EV miRNAs as early diagnostic biomarkers in patients with AMI.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: